Ischemic Heart Disease Clinical Trial
Official title:
Safety and Efficacy of Multivessel Minimally Invasive Coronary Artery Bypass Graft Surgery
Verified date | August 2017 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
the aim of this study is to evaluate safety and efficacy of multivessel minimally invasive coronary artery bypass graft surgery through evaluating the possibility of reaching complete revascularization , the complications during surgery and the outcomes
Status | Not yet recruiting |
Enrollment | 60 |
Est. completion date | October 1, 2019 |
Est. primary completion date | October 1, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age 18 or more 2. Angiographically Indication for revascularization based upon symptoms of angina and/or objective evidence of myocardial ischemia 3. Suitable minimally invasive coronary surgery (MICS) candidate for non-emergent first time, single or multivessel coronary artery bypass grafting (on pump or off pump) 4. Willing and able to provide written informed consent and comply with study requirements and accepting the need of conversion if needed. 5. Patient is willing to comply with all follow-up visits Exclusion Criteria: 1. Severe congestive heart failure (class III or IV according to NYHA, or pulmonary edema, cardiogenic shock) at the time of enrollment. 2. Prior surgery with the opening of pericardium or pleura. 3. Prior stroke (within 6 months)or more than 6 months if there are substantial neurological defects. 4. Acute ST-elevation MI within 72 hours prior to enrollment requiring revascularization. 5. Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g. valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stenting). 6. Contraindication to either CABG, MIDCAB or PCI/DES because of a coexisting clinical condition. 7. Significant leukopenia, neutropenia, thrombocytopenia, anemia, or known bleeding diathesis. 8. Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine 9. Extra-cardiac illness that is expected to limit survival to less than 5 years e.g. oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or significant hepatic failure, severe renal disease. 10. Suspected pregnancy. A pregnancy test will be administered prerandomization to all women of child-bearing age. 11. Patient inaccessible for follow-up visits required by protocol. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Mohammed Farouk Abdel Hafez |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measuring rate of intraoperative complications occurrence | measuring the rate of complications as bleeding , failure of complete revascularization and cardiac arrest during operation | 2 years | |
Primary | measuring rate of intraoperative conversion to open sternotomy | 2 years | ||
Primary | measuring amount of post operative bleeding | measuring the amount of bleeding in the drains in 48 hours post operative in cc | 2 years | |
Primary | measuring post operative pain | measuring pain using wong-baker faces pain rating scale | 2 years | |
Primary | measuring rate of reexploration | measuring the need of reexploration of the patient due to post operative massive bleeding | 2 years | |
Primary | measuring rate of wound infection | 2 years | ||
Primary | calculating days of postoperative hospital stay | 2 years | ||
Primary | calculating time to regain normal activity | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT06002932 -
Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions.
|
N/A | |
Active, not recruiting |
NCT04562805 -
Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT)
|
N/A | |
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Completed |
NCT03076801 -
Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease?
|
N/A | |
Not yet recruiting |
NCT04153383 -
Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
|
||
Recruiting |
NCT02982434 -
The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation
|
Phase 2 | |
Recruiting |
NCT02729064 -
Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose
|
Phase 1 | |
Completed |
NCT02468401 -
Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions
|
N/A | |
Completed |
NCT02759406 -
Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study
|
N/A | |
Recruiting |
NCT01681381 -
Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization
|
N/A | |
Completed |
NCT01699802 -
Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa)
|
N/A | |
Completed |
NCT01604213 -
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease
|
Phase 4 | |
Completed |
NCT01334268 -
RESOLUTE China RCT
|
N/A | |
Completed |
NCT01724567 -
Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training
|
N/A | |
Completed |
NCT02159235 -
Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD)
|
N/A |